The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Open accessAbstract
The cognitive hallmark of early Alzheimer's disease (AD) is an extraordinary inability to form new memories. For many years, this dementia was attributed to nerve-cell death induced by deposits of fibrillar amyloid beta (Abeta). A newer hypothesis has emerged, however, in which early memory loss is considered a synapse failure caused by soluble Abeta oligomers. Such oligomers rapidly block long-term potentiation, a classic experimental paradigm for synaptic plasticity, and they are strikingly elevated in AD brain tissue and transgenic-mouse AD models. The current work characterizes the manner in which Abeta oligomers attack neurons. Antibodies raised against synthetic oligomers applied to AD brain sections were found to give diffuse stain around neuronal cell bodies, suggestive of a dendritic pattern, whereas soluble brain extracts showed robust AD-dependent reactivity in dot immunoblots. Antigens in unfractionated AD extracts attached with specificity to cultured rat hippocampal neurons, binding within dendritic arbors at discrete puncta. Crude fractionation showed ligand size to be between 10 and 100 kDa. Synthetic Abeta oligomers of the same size gave identical punctate binding, which was highly selective for particular neurons. Image analysis by confocal double-label immunofluorescence established that >90% of the punctate oligomer binding sites colocalized with the synaptic marker PSD-95 (postsynaptic density protein 95). Synaptic binding was accompanied by ectopic induction of Arc, a synaptic immediate-early gene, the overexpression of which has been linked to dysfunctional learning. Results suggest the hypothesis that targeting and functional disruption of particular synapses by Abeta oligomers may provide a molecular basis for the specific loss of memory function in early AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite ongoing debate, Aβ accumulation, whether in the form of insoluble plaques, or smaller soluble oligomers does appear to be a primary driver of the disease process, particularly linked to synapse dysfunction [3].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, overexpression of APP and its proteolytic product, Aβ, have been implicated in the synaptic losses seen early in the development of AD [27].”
From FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein (2007) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other suggested Aβ binding partners at synapses include the α7-nicotinic receptor [49], Ephrin A4 [73], PSD95 [35, 50, 52] and LilrB2 [32].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [35]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“As previously discussed, amyloid-β oligomers bind to synapses [144] and interfere with the normal process of neurotransmission, long-term potentiation, and thereby memory formation [145].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [144]
In the citing paper
“Immunohistochemistry confirms that oligomers associate with neurons, accumulating very early in disease progression (Lacor et al., 2004), in loci distinct from amyloid deposits (Kayed et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“as have the related predictions that oligomers cause dysfunctional trafficking of ionotropic glutamate receptors and metabotropic glutamate receptors (Gong et al., 2003; Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“The possible source of extracellular oligomers and how they interact with neurons in human brain are suggested by their peri-somatic localization, observed in early-stage disease (Figure 1, left; (Lacor et al., 2004)).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“The same binding specificity and punctate pattern is observed for synthetic oligomers, particularly those greater than 50 kDa (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Oligomers show > 90% co-localization with the post-synaptic marker PSD-95 (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“This prediction was first confirmed for NMDA-Rs (Lacor et al., 2004; Lacor et al., 2007; Snyder et al., 2005).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“One rapid consequence is an aberrant expression of Arc (Activity-Regulated Cytoskeletal associated protein; (Lacor et al., 2004)).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Because Arc is an actin binding protein, its aberrant expression was predicted to disrupt receptor trafficking (Lacor et al., 2004), which could consequently disrupt plasticity (Gong et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Coupled with the potential of dendrites for activity-stimulated exocytosis (Kennedy et al., 2010), such a phenomenon could account for the “perineuronal deposits” of oligomers seen in Figure 1 (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“All of these processes are affected by Aβ oligomers in vitro, using primary neuronal cultures (12, 15, 36, 37).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [37]
In the citing paper
“Furthermore, extracellular Aβ1-42 oligomers preferentially target synapses when added to neurons [43, 91].”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [91]
In the citing paper
“Other binding partners that have been suggested to bind Aβ include the α7-nicotinic receptor [49], Ephrin A4 (EphA4) [73], PSD95 [35, 50, 52] or LilrB2 [32].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citationPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Research works printed but not linked: 2
- Klein WL (2004) Cytotoxic intermediates in the fibrillation pathway: Aβ oligomers in Alzheimer's disease as a case study. In: Protein misfolding, aggregation and conformational diseases (Uversky V, ed). New York: Kluwer Academic/Plenum, in press.
- 2002, Nat Rev Neurosci, 3, 824
Cited by
Sorted by citations
Items 401–500 of 949
Keowkase, R., Aboukhatwa, M. A., & Luo, Y. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.008 · Cited by 58
Hu, M., Schurdak, M. E., Puttfarcken, P. S., Kouhen, R. E., Gopalakrishnan, M., & Li, J. (2007) · Brain Research · doi:10.1016/j.brainres.2007.03.051 · Cited by 60
Nordberg, A. K. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt96 · Cited by 58
Molecular Modulation of Human α7 Nicotinic Receptor by Amyloid-β Peptides
Lasala, M., Fabiani, C., Corradi, J., Antollini, S. S., & Bouzat, C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00037 · Cited by 59
BACE-1 inhibition by a series of ψ[CH2NH] reduced amide isosteres
Coburn, C. A., Stachel, S. J., Jones, K. G., Steele, T. G., Rush, D. M., DiMuzio, J. M., Pietrak, B., Lai, M., Huang, Q., Lineberger, J. E., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.04.076 · Cited by 58
Nicotinic Receptors, Amyloid-β, and Synaptic Failure in Alzheimer’s Disease
Jürgensen, S., & Ferreira, S. T. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9237-0 · Cited by 59
Pitt, J. E., Thorner, M. O., Brautigan, D. L., Larner, J., & Klein, W. L. (2012) · The FASEB Journal · doi:10.1096/fj.12-211896 · Cited by 58
Self-citationPlasma amyloid-β oligomers level is a biomarker for Alzheimer’s disease diagnosis
Zhou, L., Chan, K. H., Chu, L., Kwan, J., Song, Y., Chen, L. H., Ho, P. W., Cheng, O., Ho, J. W.-M., & Lam, K. S. L. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.017 · Cited by 59
AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly
Sokolow, S., Henkins, K. M., Bilousova, T. V., Miller, C. A., Vinters, H. V., Poon, W. W., Cole, G. M., & Gylys, K. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.011 · Cited by 61
Sinnen, B. L., Bowen, A. B., Gibson, E. S., & Kennedy, M. J. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1603-16.2016 · Cited by 59
Cui, J., Shan, R., Cao, Y., Zhou, Y., Liu, C., & Fan, Y. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113466 · Cited by 57
Rhein, V., & Eckert, A. (2007) · Archives of Physiology and Biochemistry · doi:10.1080/13813450701572288 · Cited by 56
Intracellular calcium signalling in Alzheimer’s disease
Hermes, M., Eichhoff, G., & Garaschuk, O. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00976.x · Cited by 57
Pain, C., Dumont, J., & Dumoulin, M. (2015) · Biochimie · doi:10.1016/j.biochi.2015.01.012 · Cited by 60
Rohn, T. T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140714908 · Cited by 58
Zhang, Y., Huang, L., Shi, S., Xu, S., Wang, X., & Peng, Y. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12594 · Cited by 56
The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's Disease
Rohn, T. T., Kim, N., Isho, N. F., & Mack, J. M. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000439 · Cited by 58
An update on potential links between type 2 diabetes mellitus and Alzheimer’s disease
Sousa, R. A. L. D., Harmer, A. R., Freitas, D. A., Mendonça, V. A., Lacerda, A. C. R., & Leite, H. R. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05693-z · Cited by 57
Calcium in the initiation, progression and as an effector of Alzheimer’s disease pathology
Green, K. N. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00861.x · Cited by 56
Hara, M., Hirokawa, K., Kamei, S., & Uchihara, T. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1097-6 · Cited by 55
Liu, X.-G., Zhang, L., Lu, S., Liu, D.-Q., Zhang, L.-X., Yu, X.-L., & Liu, R.-T. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s240953 · Cited by 55
Hurst, C. D., Pugh, D. A., Abreha, M. H., Duong, D. M., Dammer, E. B., Bennett, D. A., Herskowitz, J. H., & Seyfried, N. T. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100542 · Cited by 56
Childhood and adolescent obesity and long‐term cognitive consequences during aging
Wang, J., Freire, D., Knable, L. A., Zhao, W., Gong, B., Mazzola, P., Ho, L., Levine, S., & Pasinetti, G. M. (2014) · The Journal of Comparative Neurology · doi:10.1002/cne.23708 · Cited by 55
A New Player in the “Synaptopathy” of Alzheimer’s Disease – Arc/Arg 3.1
Kerrigan, T. L., & Randall, A. D. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00009 · Cited by 57
Calcium dyshomeostasis and neurotoxicity of Alzheimer’s β-amyloid protein
Kawahara, M., Kato‐Negishi, M., & Sadakane, Y. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.28 · Cited by 57
Amyloid-β(25-35) Modulates the Expression of GirK and KCNQ Channel Genes in the Hippocampus
Mayordomo‐Cava, J., Yajeya, J., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134385 · Cited by 55
Zhong, Y., Zhu, Y., He, T., Li, W., Li, Q., & Miao, Y. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3933 · Cited by 55
Velasco, P. T., Heffern, M. C., Sebollela, A. S., Popova, I. A., Lacor, P. N., Lee, K. B., Sun, X., Tiano, B. N., Viola, K. L., Eckermann, A. L., et al. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300122k · Cited by 57
Self-citationEsfandiari, E., Karimipour, M., Mardani, M., Alaei, H., Ghanadian, M., Kazemi, M., Mohammadnejad, D., Hosseini, N., & Esmaeili, A. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23319 · Cited by 54
Upadhaya, A. R., Capetillo‐Zarate, E., Kosterin, I., Abramowski, D., Kumar, S., Yamaguchi, H., Walter, J., Fändrich, M., Staufenbiel, M., & Thal, D. R. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.032 · Cited by 54
Lizama, B. N., Kahle, J., Catalano, S. M., Caggiano, A. O., Grundman, M., & Hamby, M. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076251 · Cited by 54
Role of primary aging hallmarks in Alzheimer´s disease
Zhao, J., & Huai, J. (2022) · Theranostics · doi:10.7150/thno.79535 · Cited by 55
Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons
Shughrue, P. J., Acton, P. J., Breese, R., Zhao, W., Chen-Dodson, E., Hepler, R. W., Wolfe, A. L., Matthews, M., Heidecker, G. J., Joyce, J. G., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.003 · Cited by 53
Dinamarca, M. C., Weinstein, D. B., Monasterio, O., & Inestrosa, N. C. (2011) · Biochemistry · doi:10.1021/bi201246t · Cited by 53
Shahidi, ., Asl, S. S., Komaki, A., & Hashemi-Firouzi, N. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4862-3 · Cited by 54
Alzheimer’s Disease: A Molecular View of β-Amyloid Induced Morbific Events
Asik, R. M., Suganthy, N., Aarifa, M. A., Kumar, A., Szigeti, K., Máthé, D., Gulyás, B. Z., Archunan, G., & Padmanabhan, P. (2021) · Biomedicines · doi:10.3390/biomedicines9091126 · Cited by 54
Evans, N. A., Facci, L., OWEN, D. E., Soden, P. E., Burbidge, S. A., Prinjha, R. K., Richardson, J. C., & Skaper, S. D. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.08.001 · Cited by 56
Singer, S. J., & Dewji, N. N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509892103 · Cited by 53
Taniguchi, K., Yamamoto, F., Amano, A., Tamaoka, A., Sanjo, N., Yokota, T., Kametani, F., & Araki, W. (2022) · Neuroscience Research · doi:10.1016/j.neures.2022.03.001 · Cited by 57
Zolezzi, J. M., Candia, S. B., Santos, M. J., & Inestrosa, N. C. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00176 · Cited by 56
Type-2 alkenes mediate synaptotoxicity in neurodegenerative diseases
LoPachin, R. M., Gavin, T., & Barber, D. S. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.04.016 · Cited by 53
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecı̀ć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 54
Self-citationSynaptic Compensatory Plasticity in Alzheimer’s Disease
Bhembre, N., Bonthron, C., & Opazo, P. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0379-23.2023 · Cited by 56
Expression and Localization of Mitochondrial Ferritin mRNA in Alzheimer's Disease Cerebral Cortex
Wang, L., Yang, H., Zhao, S., Sato, H., Konishi, Y., Beach, T. G., Abdelalim, E. M., Bisem, N. J., & Tooyama, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022325 · Cited by 51
Rózga, M., & Bal, W. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900358j · Cited by 54
Meli, G., Lecci, A., Manca, A., Jakovljevic, N. K., Albertini, V., Benussi, L., Ghidoni, R., & Cattaneo, A. (2014) · Nature Communications · doi:10.1038/ncomms4867 · Cited by 51
Ashley, R. H., Harroun, T. A., Hauß, T., Breen, K. C., & Bradshaw, J. P. (2006) · BMC Structural Biology · doi:10.1186/1472-6807-6-21 · Cited by 52
Amyloid beta plaque: a culprit for neurodegeneration
Gupta, A., & Goyal, R. (2016) · Acta Neurologica Belgica · doi:10.1007/s13760-016-0639-9 · Cited by 51
Liu, X., Zhang, L., Lü, S., Liu, D., Huang, Y., Zhu, J., Zhou, W.-W., Yu, X., & Liu, R. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00723-1 · Cited by 51
RetractedMAGUK proteins: New targets for pharmacological intervention in the glutamatergic synapse
Gardoni, F. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.048 · Cited by 53
Madhu, P., & Mukhopadhyay, S. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30141 · Cited by 53
Proctor, D. T., Coulson, E. J., & Dodd, P. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.02.002 · Cited by 53
Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer’s Disease
Sellés, M. C., Oliveira, M. M., & Ferreira, S. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179925 · Cited by 51
VEGF counteracts amyloid-β-induced synaptic dysfunction
Martin, L., Bouvet, P., Chounlamountri, N., Watrin, C., Besançon, R., Pinatel, D., Meyronet, D., Honnorat, J., Buisson, A., Salin, P. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109121 · Cited by 52
Husain, N., Yuan, Q., Yen, Y.-C., Pletniková, O., Sally, D. Q., Worley, P. F., Bichler, Z., & Je, H. S. (2016) · Aging Cell · doi:10.1111/acel.12551 · Cited by 51
Modulation of Amyloid‐β Aggregation by Histidine‐Coordinating Cobalt(III) Schiff Base Complexes
Heffern, M. C., Velasco, P. T., Matosziuk, L. M., Coomes, J. L., Karras, C. L., Ratner, M. A., Klein, W. L., Eckermann, A. L., & Meade, T. J. (2014) · ChemBioChem · doi:10.1002/cbic.201402201 · Cited by 50
Self-citationAnker, J. N., Hall, W. P., Lambert, M. P., Velasco, P. T., Mrksich, M., Klein, W. L., & Duyne, R. P. V. (2009) · The Journal of Physical Chemistry C · doi:10.1021/jp900266k · Cited by 48
Self-citationRohn, T. T. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/860959 · Cited by 51
Unraveling Prion Protein Interactions with Aptamers and Other PrP-Binding Nucleic Acids
Macedo, B., & Cordeiro, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051023 · Cited by 48
Neuronal spreading and plaque induction of intracellular Aβ and its disruption of Aβ homeostasis
Roos, T. T., Garcia, M. G., Martinsson, I., Mabrouk, R., Israelsson, B., Deierborg, T., Kobro‐Flatmoen, A., Tanila, H., & Gouras, G. K. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02345-9 · Cited by 48
Early Molecular Changes in Alzheimer Disease: Can We Catch the Disease in its Presymptomatic Phase?
Wirz, K. T. S., Keitel, S., Swaab, D. F., Verhaagen, J., & Bossers, K. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130920 · Cited by 47
Down‐regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease
Rodriguez‐Perdigon, M., Tordera, R. M., Gil-Bea, F. J., Gereñu, G., Ramírez, M. J., & Solas, M. (2016) · Hippocampus · doi:10.1002/hipo.22607 · Cited by 49
Zhang, L., Trushin, S., Christensen, T. A., Tripathi, U., Hong, C. C., Geroux, R. E., Howell, K. G., Poduslo, J. F., & Trushina, E. V. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.02.003 · Cited by 50
Kelly, L., Seifi, M., Ma, R., Mitchell, S. J., Rudolph, U., Viola, K. L., Klein, W. L., Lambert, J. J., & Swinny, J. D. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12674 · Cited by 48
Self-citationWang, Z., Zheng, P., Xie, Y., Chen, X., Solowij, N., Green, K., Chew, Y. L., & Huang, X. (2021) · The FASEB Journal · doi:10.1096/fj.202002724r · Cited by 48
Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities
Li, S., & Stern, A. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01589-5 · Cited by 47
Bignante, E. A., Heredia, F., Morfini, G. A., & Lorenzo, A. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.021 · Cited by 50
Saadipour, K., Yang, M., Lim, Y. P., Georgiou, K. R., Sun, Y., Keating, D. J., Liu, J., Wang, Y., Gai, W., Zhong, J., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12383 · Cited by 52
The Potential Role of Rho GTPases in Alzheimer's Disease Pathogenesis
Bolognin, S., Lorenzetto, E., Diana, G., & Buffelli, M. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8637-5 · Cited by 47
Capetillo-Zarate, E., Staufenbiel, M., Abramowski, D., Haass, C., Escher, A., Stadelmann, C., Yamaguchi, H., Wiestler, O. D., & Thal, D. R. (2006) · Brain · doi:10.1093/brain/awl176 · Cited by 45
Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis
Almeida, Z. L., Vaz, D. C., & Brito, R. M. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04543-4 · Cited by 49
Anti-Amyloidogenic Properties of Some Phenolic Compounds
Porzoor, A., Alford, B. L., Hügel, H., Grando, D., Caine, J. M., & Macreadie, I. G. (2015) · Biomolecules · doi:10.3390/biom5020505 · Cited by 46
Basi, G. S., Feinberg, H., Oshidari, F., Anderson, J., Barbour, R., Baker, J., Comery, T. A., Diep, L., Gill, D. S., Johnson‐Wood, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.045187 · Cited by 45
Rishton, G. M., Look, G. C., Ni, Z., Zhang, J. Y., Wang, Y., Huang, Y., Wu, X., Izzo, N. J., Mozzoni, K., Limegrover, C. S., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00048 · Cited by 45
The Role of Reelin Signaling in Alzheimer’s Disease
Yu, N., Tan, M., Yu, J., Xie, A., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9459-9 · Cited by 47
Helmond, Z. V., Heesom, K. J., & Love, S. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.09.002 · Cited by 44
The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy
Peña‐Ortega, F., Gutiérrez-Lerma, A. I., Quiroz‐Baez, R., & Arias, C. (2006) · Current Neuropharmacology · doi:10.2174/157015906776359531 · Cited by 45
Regulation of spine structural plasticity by Arc/Arg3.1
Newpher, T. M., Harris, S. C., Pringle, J., Hamilton, C., & Soderling, S. H. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.09.022 · Cited by 45
Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease
Wirths, O., & Zampar, S. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1702972 · Cited by 44
Nanotechnology‐Based Strategies for Early Diagnosis of Central Nervous System Disorders
Hanif, S., Muhammad, P., Niu, Z., Ismail, M., Morsch, M., Zhang, X., Li, M., & Shi, B. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100008 · Cited by 44
Optogenetics: implications for Alzheimer’s disease research and therapy
Mirzayi, P., Shobeiri, P., Kalantari, A., Perry, G. L., & Rezaei, N. (2022) · Molecular Brain · doi:10.1186/s13041-022-00905-y · Cited by 45
Lipid-Induced β-Amyloid Peptide Assemblage Fragmentation
Widenbrant, M. J. O., Rajadas, J., Sutardja, C., & Fuller, G. G. (2006) · Biophysical Journal · doi:10.1529/biophysj.106.085944 · Cited by 44
PGH2‐derived levuglandin adducts increase the neurotoxicity of amyloid β1–42
Boutaud, O. G., Montine, T. J., Chang, L., Klein, W. L., & Oates, J. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03586.x · Cited by 44
Self-citationTransmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease
Colom-Cadena, M., Toombs, J., Simzer, E., Holt, K., McGeachan, R., Tulloch, J., Jackson, R. J., Catterson, J. H., Spires-Jones, M. P., Rose, J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02679-6 · Cited by 44
Alzheimer’s Disease and Protein Kinases
Engin, A. B., & Engin, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49844-3_11 · Cited by 43
Zhang, L., Sui, H., Liang, B., Wang, H., Qu, W., Yu, S., & Jin, Y. H. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.203 · Cited by 43
Postsynaptic Proteome of Non-Demented Individuals with Alzheimer’s Disease Neuropathology
Zolochevska, O., Bjorklund, N., Woltjer, R., Wiktorowicz, J. E., & Taglialatela, G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180179 · Cited by 42
Membrane cholesterol enrichment prevents Aβ-induced oxidative stress in Alzheimer's fibroblasts
Pensalfini, A., Zampagni, M., Liguri, G., Becatti, M., Evangelisti, E., Fiorillo, C., Bagnoli, S., Cellini, E., Nacmias, B., Sorbi, S., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.010 · Cited by 43
Pifer, P. M., Yates, E. A., & Legleiter, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016248 · Cited by 43
Olofsson, A., Lindhagen‐Persson, M., Vestling, M., Sauer-Eriksson, A. E., & Öhman, A. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07113.x · Cited by 42
Colombo, R., Carotti, A., Catto, M., Racchi, M., Lanni, C., Verga, L., Caccialanza, G., & Lorenzi, E. D. (2009) · Electrophoresis · doi:10.1002/elps.200800377 · Cited by 44
Gospodarska, E., Kupniewska-Kozak, A., Goch, G., & Dadlez, M. (2011) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.02.011 · Cited by 42
Pérez, J. L. M., Carrero, I., Gonzalo, P., Arévalo‐Serrano, J., Anquela, J. M. S., Ortega, F. J., Rodríguez, M. J., & Gonzalo‐Ruiz, A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.10.013 · Cited by 44
Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?
Bayer, T. A., & Wirths, O. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390857 · Cited by 41
Liu, Z., Wang, W., Feng, N., Wang, L., Shi, J., & Wang, X. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.03.009 · Cited by 41
The Inside-Out Amyloid Hypothesis and Synapse Pathology in Alzheimer's Disease
Gouras, G. K., Willén, K. I., & Faideau, M. (2013) · Neurodegenerative Diseases · doi:10.1159/000354776 · Cited by 42
Ajmo, J. M., Bailey, L. A., Howell, M. D., Cortez, L. K., Pennypacker, K. R., Mehta, H. N., Morgan, D., Gordon, M. N., & Gottschall, P. E. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06647.x · Cited by 41
Lou, G., ZHANG, Q.-H., Xiao, F., Xiang, Q., Su, Z., Zhang, L., Yang, P., Yang, Y. F., Zheng, Q., & Huang, Y. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.08.003 · Cited by 40
Isolation of synaptic terminals from Alzheimer's disease cortex
Sokolow, S., Henkins, K. M., Williams, I., Vinters, H. V., Schmid, I., Cole, G. M., & Gylys, K. H. (2011) · Cytometry Part A · doi:10.1002/cyto.a.22009 · Cited by 40
Kumar, A., Paslay, L. C., Lyons, D. F., Morgan, S. E., Correia, J. J., & Rangachari, V. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.355156 · Cited by 43
Metadata
- Authors
- Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., Krafft, G. A., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- University of Southern California (US)
- Acumen Pharmaceuticals (United States) (US)
- Corresponding author
- Klein, William L.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2004-11-10
- Volume
- 24
- Issue
- 45
- Pages
- 10191-10200
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6730194
- OpenAlex
- W2162807572
- Cited by
- 954
- References
- 64
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 24 · 2023: 41 · 2022: 35 · 2021: 28 · 2020: 26 · 2019: 32 · 2018: 41 · 2017: 50 · 2016: 51 · 2015: 50 · 2014: 54 · 2013: 65 · 2012: 59
- FWCI
- 25.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Illinois Department of Public Health
- Northwestern University
- National Institutes of Health (AG11385)
- National Institute on Aging (R01 AG11385, P30AG13854, R01AG022547, R01-AG22547, R01AG011385, R03AG022237, R01-AG18877, P30AG013854, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, synaptic targeting, long-term potentiation, synaptic plasticity, PSD-95, Arc, hippocampal neurons, memory loss, early Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Animals, Binding Sites, Cerebral Cortex, Cerebrospinal Fluid Proteins, Chromatography, High Pressure Liquid, Cytoskeletal Proteins, Female, Hippocampus, Humans, Male, Nerve Tissue Proteins, Neurons, Peptide Fragments, Protein Binding, Synapses, Tissue Extracts, Amyloid beta-Peptides, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
